# CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.

> **NCT03067155** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 1 (actual)

## Conditions studied

- Hematological Malignancies
- CMV Infection

## Interventions

- **GENETIC:** CMV-specific T cells
- **DRUG:** Standard anti-viral therapy

## Key facts

- **NCT ID:** NCT03067155
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067155, "CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03067155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*